A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)

No significant difference was found between the intraocular pressure (IOP) lowering of omidenepag isopropyl 0.002% once daily (QD) and twice daily (BID). However, adverse events (AEs) were higher in the BID arm; thus, QD dosing is the preferred dosing frequency for further investigation. PURPOSE: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Olander, Kenneth W., Sato, Michelle A., Abrams, Marc A., Jerkins, Gary W., Lu, Fenghe, Dinh, Phillip, Odani-Kawabata, Noriko, Chabi, Almira, Shams, Naveed K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Medical and Surgical Glaucoma: Original Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171257/
https://www.ncbi.nlm.nih.gov/pubmed/33813559
http://dx.doi.org/10.1097/IJG.0000000000001836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171257/
https://www.ncbi.nlm.nih.gov/pubmed/33813559
http://dx.doi.org/10.1097/IJG.0000000000001836

Ejemplares similares